QCG
BMRN icon

Quadrant Capital Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Quadrant Capital Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,772
Closed -$1.17M – 1424
2026
Q1 		$1.17M Buy
20,772
+1,436
+7% +$83.7K 0.04% 493
2025
Q4 		$1.15M Buy
19,336
+14,918
+338% +$812K 0.03% 477
2025
Q3 		$239K Sell
4,418
-7,740
-64% -$443K 0.01% 1214
2025
Q2 		$668K Buy
12,158
+1,148
+10% +$67.6K 0.02% 695
2025
Q1 		$778K Buy
11,010
+9,234
+520% +$621K 0.03% 490
2024
Q4 		$117K Buy
1,776
+658
+59% +$44.1K 0.01% 976
2024
Q3 		$78.6K Buy
1,118
+687
+159% +$57.4K 0.01% 1217
2024
Q2 		$35.5K Buy
431
+266
+161% +$22.1K ﹤0.01% 1579
2024
Q1 		$14.4K Buy
165
+14
+9% +$1.25K ﹤0.01% 1979
2023
Q4 		$14.6K Buy
151
+19
+14% +$1.68K ﹤0.01% 1929
2023
Q3 		$11.7K Sell
132
-327
-71% -$29.1K ﹤0.01% 1933
2023
Q2 		$39.8K Sell
459
-62
-12% -$5.83K ﹤0.01% 1374
2023
Q1 		$50.7K Buy
521
+290
+126% +$30.1K 0.01% 1237
2022
Q4 		$23.9K Sell
231
-17
-7% -$1.6K ﹤0.01% 1578
2022
Q3 		$21K Sell
248
-107
-30% -$9.53K ﹤0.01% 1501
2022
Q2 		$29K Buy
355
+232
+189% +$18.5K ﹤0.01% 1113
2022
Q1 		$9K Sell
123
-120
-49% -$10K ﹤0.01% 1680
2021
Q4 		$21K Buy
243
+8
+3% +$660 ﹤0.01% 1279
2021
Q3 		$18K Sell
235
-10
-4% -$789 ﹤0.01% 1281
2021
Q2 		$20K Sell
245
-104
-30% -$8.24K ﹤0.01% 1194
2021
Q1 		$26K Buy
349
+115
+49% +$9.39K ﹤0.01% 1067
2020
Q4 		$21K Sell
234
-13
-5% -$1.03K ﹤0.01% 1074
2020
Q3 		$19K Sell
247
-521
-68% -$52.7K ﹤0.01% 967
2020
Q2 		$95K Sell
768
-854
-53% -$84.9K 0.02% 471
2020
Q1 		$137K Buy
1,622
+1,111
+217% +$95.7K 0.02% 474
2019
Q4 		$41K Sell
511
-432
-46% -$32.6K ﹤0.01% 1431
2019
Q3 		$62K Sell
943
-940
-50% -$72.4K 0.01% 1134
2019
Q2 		$156K Buy
1,883
+643
+52% +$55K 0.02% 671
2019
Q1 		$105K Buy
1,240
+880
+244% +$81.6K 0.02% 780
2018
Q4 		$26K Sell
360
-82
-19% -$7.8K 0.01% 1097
2018
Q3 		$38K Hold
442
– – 0.01% 742
2018
Q2 		$36K Buy
442
+113
+34% +$9.9K 0.01% 761
2018
Q1 		$21K Sell
329
-30
-8% -$2.58K 0.01% 933
2017
Q4 		$27K Sell
359
-95
-21% -$8.26K 0.01% 818
2017
Q3 		$36K Buy
454
+52
+13% +$4.59K 0.01% 701
2017
Q2 		$31K Buy
402
+81
+25% +$7.37K 0.01% 708
2017
Q1 		$23K Buy
321
+48
+18% +$4.27K 0.01% 784
2016
Q4 		$17K Sell
273
-59
-18% -$5.07K 0.01% 811
2016
Q3 		$26K Hold
332
– – 0.02% 655
2016
Q2 		$22K Buy
332
+196
+144% +$16.7K 0.02% 662
2016
Q1 		$9K Buy
136
+31
+30% +$2.52K 0.01% 991
2015
Q4 		$8K Buy
105
+27
+35% +$2.82K 0.01% 866
2015
Q3 		$8K Buy
+78
New +$10.4K 0.01% 719

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Quadrant Capital Group's BMRN Position: Q2 2026 in Review

Quadrant Capital Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 20,772 shares — an estimated $1.17M sold.

Quadrant Capital Group first reported a position in BMRN in Q3 2015 and held it in 43 quarters. The position peaked at $1.17M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Quadrant Capital Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 20,772 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.17M.
  • Quadrant Capital Group first reported a position in BioMarin Pharmaceuticals in Q3 2015 and held it in 43 quarters.
  • Quadrant Capital Group's BioMarin Pharmaceuticals position peaked at $1.17M in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.